Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Bids To Be A Winner In Cell & Gene Therapy

Adopts Four-Pillar Strategy

Executive Summary

The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.

You may also be interested in...



Xarelto Still Climbs As Bayer Touts Successor

Bayer's pharmaceuticals chief Stefan Oelrich says that sales of treatments in the areas of ophthalmology, women’s healthcare and radiology have risen sharply, recovering from the effects of the COVID-19 pandemic.

The Top Five (Non-COVID) Pharma Stories Of 2021

The emergence and rapid spread of the Omicron variant has kept COVID-19 firmly in the headlines but the biopharma industry has had plenty on its plate on top of tackling the pandemic. Scrip has taken a look back at five of the biggest non-COVID-19 story themes of 2021 in no particular order.

Bayer Back In Radiopharmaceuticals Ring With Noria Buy

Although Bayer's radiopharmaceutical for prostate cancer Xofigo has proved a commercial disappointment, the Leverkusen-headquartered firm is keen to advance its pipeline of targeted alpha therapies, snapping up Noria and its subsidiary PSMA Therapeutics.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel